Journal of Clinical Oncology, Vol 12, 2360-2366, Copyright © 1994 by American Society of Clinical Oncology

ARTICLES

Synovial sarcoma in children and adolescents: the St Jude Children's Research Hospital experience

AS Pappo, J Fontanesi, X Luo, BN Rao, DM Parham, C Hurwitz, L Avery and CB Pratt
Department of Hematology-Oncology, St Jude Children's Research Hospital, Memphis, TN 38101-0318.

PURPOSE AND METHODS: We reviewed the clinical records and pathologic findings of 37 children and adolescents with synovial sarcoma treated at our institution over a 30-year period to evaluate the prognostic significance of tumor size, invasiveness, histology, and other features. RESULTS: The 20 male and 17 female patients with synovial sarcoma had a median age of 13.7 years at diagnosis. Primary tumor sites were the extremities (n = 27), trunk (n = 8), and head and neck (n = 2). Disease stage (clinical group) was as follows: group I, n = 21; group II, n = 7; group III, n = 4; and group IV, n = 5. Nineteen patients had invasive (T2) lesions, 20 had tumors more than 5 cm in diameter, and 14 had histologic grade 3 lesions. The estimated 5-year survival rate (+/- SE) for patients with group I or II disease was 80% +/- 9%, compared with 17% +/- 15% for those with group III or IV tumors (P = .0003). An exact log-rank test, adjusted for clinical group, showed that tumor invasiveness and grade independently predicted overall and progression-free survival (P < .05); tumor size was significantly correlated with progression-free survival. A borderline significant relationship with overall survival was found for both tumor size and histologic subtype (P = .09). CONCLUSION: A controlled trial of adjuvant chemotherapy is merited in children with resected synovial sarcoma (clinical group I or II) who present with unfavorable clinicopathologic features such as large, invasive, or grade 3 lesions. Children with unresected or metastatic disease fare poorly despite multimodality therapy and require novel treatment approaches.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. F. Okcu, M. Munsell, J. Treuner, A. Mattke, A. Pappo, A. Cain, A. Ferrari, M. Casanova, A. Ozkan, and B. Raney Synovial Sarcoma of Childhood and Adolescence: A Multicenter, Multivariate Analysis of Outcome J. Clin. Oncol., April 15, 2003; 21(8): 1602 - 1611. [Abstract] [Full Text] [PDF]

				J. J. Lewis, C. R. Antonescu, D. H. Y. Leung, D. Blumberg, J. H. Healey, J. M. Woodruff, and M. F. Brennan Synovial Sarcoma: A Multivariate Analysis of Prognostic Factors in 112 Patients With Primary Localized Tumors of the Extremity J. Clin. Oncol., May 10, 2000; 18(10): 2087 - 2094. [Abstract] [Full Text] [PDF]

				C. B. Pratt, A. S. Pappo, P. Gieser, J. J. Jenkins, J. Neff, B. Rao, D. Green, P. Thomas, R. Marcus, D. Parham, et al. Role of Adjuvant Chemotherapy in the Treatment of Surgically Resected Pediatric Nonrhabdomyosarcomatous Soft Tissue Sarcomas: A Pediatric Oncology Group Study J. Clin. Oncol., April 1, 1999; 17(4): 1219 - 1219. [Abstract] [Full Text] [PDF]

				A. Kawai, J. Woodruff, J. H. Healey, M. F. Brennan, C. R. Antonescu, and M. Ladanyi SYT-SSX Gene Fusion as a Determinant of Morphology and Prognosis in Synovial Sarcoma N. Engl. J. Med., January 15, 1998; 338(3): 153 - 160. [Abstract] [Full Text] [PDF]